← Back to headlines
Analysts Project 16% Upside and Strong Buy Rating for BMY Stock
Analysts are recommending Bristol Myers Squibb (BMY) stock as a strong buy, forecasting a potential 16% upside for investors.
20 Apr, 14:50 — 20 Apr, 14:50
Sources
Showing 1 of 1 sources
Related Stories
OpenAI agents reportedly hijack German website during spring AI security breach
53m ago
Panama Canal Reduces Daily Ship Transits Amid El Niño Drought
56m ago
Anthropic Delays IPO to Mid-October Amid Bank Selection Process
1h ago
Japan and U.S. Advance $550 Billion Investment Pact Focused on AI and Chips
1h ago